Skip to main content
Ondine Biomedical Inc. logo

Ondine Biomedical Inc. — Investor Relations & Filings

Ticker · OBI ISIN · CA68234M2058 LEI · 9845005B69E07CGF4A56 TSXV Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2024-03-15 Regulatory Filings
Country CA Canada
Listing TSXV OBI

About Ondine Biomedical Inc.

https://ondinebio.com/

Ondine Biomedical Inc. is a life sciences company that develops and commercializes photodisinfection-based therapies to prevent and treat a broad spectrum of infections, including those caused by drug-resistant pathogens. The company's patented platform technology involves applying a photosensitive agent to a targeted area, followed by illumination with non-thermal laser light. This process creates an oxidative burst that rapidly destroys pathogens like bacteria, viruses, and fungi without inducing microbial resistance. Its lead product, Steriwave™, is a nasal decolonization therapy used to eradicate pathogens in the nasal cavity, primarily to reduce the risk of healthcare-associated infections (HAIs) such as post-operative surgical site infections. The company's product pipeline is exploring applications for chronic rhinosinusitis, burns, wounds, and ventilator-associated pneumonia.

Recent filings

Filing Released Lang Actions
Steriwave deploying in eight new sites
Regulatory Filings Classification · 98% confidence The document is a press release issued via the London Stock Exchange's 'Reach' service (RNS). It provides a commercial update regarding the deployment of the company's 'Steriwave' technology in new healthcare facilities. It does not constitute a formal financial report, audit, or regulatory filing required by law, but rather a corporate news update. As it is a general regulatory announcement that does not fit into more specific categories like earnings releases or M&A, it is classified as an RNS.
2024-03-15 English
Ondine starts first UK health economics study
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the London Stock Exchange's 'Reach' service. It announces a new health economics study partnership for the company's product, Steriwave. As it is a general corporate announcement regarding business operations and partnerships that does not fit into specific financial reporting categories like 10-K or IR, and is distributed via an RNS-related service, it is classified as a Regulatory Filing (RNS).
2024-03-05 English
Microbiome research supports use of Steriwave
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the RNS Reach service, which is used for non-regulatory corporate announcements. It details scientific research findings presented by Ondine Biomedical at a conference. Since it does not fit into specific financial reporting categories like 10-K, ER, or IR, and is not a report publication announcement (it is the content itself, not a notice of a report), it falls under the general regulatory/corporate announcement category.
2024-01-31 English
Ondine unveils new research at SPIE Photonics West
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the RNS Reach service, which is explicitly labeled as a 'Non-regulatory announcement'. It details the company's participation in a scientific conference (SPIE Photonics West) and summarizes research findings. Since it does not fit into specific financial reporting categories like 10-K, ER, or IR, and is a general corporate announcement, it falls under the 'Regulatory Filings' (RNS) category as the designated fallback for miscellaneous announcements.
2024-01-26 English
Grant of Share Options
Regulatory Filings Classification · 98% confidence The document is an official announcement regarding the grant of share options to company directors and executives (PDMRs). It includes detailed tables of the options granted, exercise prices, and the required regulatory disclosures under the UK Market Abuse Regulation. While it involves directors, it is specifically a report of a transaction (grant of options) rather than a general change in board composition or a personal trade of existing shares by a director, making it a disclosure of a corporate action regarding share-based compensation. Given the specific nature of reporting transactions by PDMRs, this falls under the category of Director's Dealing (DIRS).
2024-01-26 English
Appointment of new Chief Financial Officer
Board/Management Information Classification · 100% confidence The document is an official announcement from Ondine Biomedical Inc. regarding the appointment of a new Chief Financial Officer (Joseph P. Errico). According to the filing definitions, announcements concerning changes in senior management fall under the 'Board/Management Information' (MANG) category. The document is clearly an announcement of a personnel change rather than a report publication or other financial filing.
2024-01-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.